

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

PROFIT WARNING

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, “**the Group**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform holders of the Company’s shares and securities and potential investors that, based on unaudited consolidated financial statements currently available to the Board, the Group achieved double digit year-on-year growth in sales revenue for the twelve months ended 31 December 2021 (the “**Reporting Period**”), which was principally attributable to rapid market penetration in the endovascular and peripheral vascular devices business, the cardiac rhythm management business, the neurovascular business and the heart valve business, contribution from new product launches, and the increase in elective surgeries from the easing of the COVID-19 pandemic.

During the Reporting Period, the Group recorded loss attributable to equity shareholders of the Company of between approximately USD275 million and USD285 million, as compared with a loss of USD191 million for the same period of last year. This change was principally attributable to: (i) significant increases in expenses for the surgical robot business, the heart valve business and other business segments in their active promotion of research and development, registration and commercialization with the help of their own independent financing channels; (ii) increase in investment in overseas market development and product promotion; (iii) increase in costs recognized for the incentive shares granted to certain employees under the Group’s share incentive scheme during the reporting period; and (iv) the impact brought on by China’s centralized procurement policy on coronary stents.

As at the date of this announcement, the Company is still in the process of preparing and completing the annual results of the Group for the twelve months ended 31 December 2021 (the “**2021 Annual Results**”). The information contained in this announcement is a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or audit committee of the Company. Holders of the Company’s shares and securities and potential investors are advised to read the Company’s announcement for the 2021 Annual Results carefully, which is expected to be published before the end of March 2022. Holders of the Company’s shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 4 March 2022

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*